Michael Feldschuh - Daxor CEO

DXR Stock  USD 9.50  0.05  0.52%   

CEO

Mr. Michael Richard Feldschuh serves as Chairman of the Board, President, Chief Executive Officer of the Company. He was Interim President, Chief Executive Officer of the Company. He served as the Director of the company, since 2013. Michael Feldschuh earned his bachelors degree in PreMed studies at Columbia College, Columbia University in 1991. Prior to joining Daxors executive team in December of 2014 he served as a member of the board of directors for one and a half years prior. Michael headed his own hedge fund, Aristarc Capital, from 2009 to 2013 specializing in quantitative strategies. Prior to founding his own fund, Michael was a Managing Director at Morgan Stanley from 2005 to 2009 and also served as a Managing Director and Portfolio Manager at Millennium Partners in New York from 19972005. Michael was a proprietary trader for Morgan Stanley Co. from 19941997. Michael began his career at D.E. Shaw Co. in New York, where he worked with Jeffery Bezos prior to Bezoss founding of Amazon. since 2017.
Age 55
Tenure 7 years
Address 109 Meco Lane, Oak Ridge, TN, United States, 37830
Phone212 330 8500
Webhttps://www.daxor.com

Michael Feldschuh Latest Insider Activity

Tracking and analyzing the buying and selling activities of Michael Feldschuh against Daxor stock is an integral part of due diligence when investing in Daxor. Michael Feldschuh insider activity provides valuable insight into whether Daxor is net buyers or sellers over its current business cycle. Note, Daxor insiders must abide by specific rules, including filing SEC forms every time they buy or sell Daxor'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Daxor Management Efficiency

The company has Return on Asset of (0.0151) % which means that on every $100 spent on assets, it lost $0.0151. This is way below average. Daxor's management efficiency ratios could be used to measure how well Daxor manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Daxor's Return On Tangible Assets are relatively stable compared to the past year. As of 04/16/2024, Return On Assets is likely to grow to 0.01, while Return On Capital Employed is likely to drop 0.01. At this time, Daxor's Total Assets are relatively stable compared to the past year. As of 04/16/2024, Return On Tangible Assets is likely to grow to 0.01, while Non Currrent Assets Other are likely to drop (36.6 M).
The company has 755.66 K in debt with debt to equity (D/E) ratio of 0.14, which may show that the company is not taking advantage of profits from borrowing. Daxor has a current ratio of 2.92, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Daxor until it has trouble settling it off, either with new capital or with free cash flow. So, Daxor's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Daxor sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Daxor to invest in growth at high rates of return. When we think about Daxor's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 6 records

CEO Age

April AnthonyEncompass Health Corp
53
Mark PortnoyCryoCell International
60
Stephen FlattNational HealthCare
68
Mark TarrEncompass Health Corp
62
David ChernowSelect Medical Holdings
67
Christopher ChristensenThe Ensign Group
55
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corp is traded on NASDAQ Exchange in the United States. Daxor (DXR) is traded on NASDAQ Exchange in USA. It is located in 109 Meco Lane, Oak Ridge, TN, United States, 37830 and employs 18 people. Daxor is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Daxor Leadership Team

Elected by the shareholders, the Daxor's board of directors comprises two types of representatives: Daxor inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Daxor. The board's role is to monitor Daxor's management team and ensure that shareholders' interests are well served. Daxor's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Daxor's outside directors are responsible for providing unbiased perspectives on the board's policies.
CPA CPA, Chief CFO
James Lombard, Independent Director
Michael Feldschuh, Interim CEO, Interim President, Head of Bus. Devel. and Strategic Initiatives and Director
Joseph Feldschuh, Chairman of the Board and Presidentident
Joy Goudie, Independent Director
Jean Oertel, Senior Experience
Bernhard Saxe, Independent Director
Guido Manzo, Vice Sales
Diane Meegan, Corporate Secretary
Robert Michel, Chief Financial Officer
Henry Cremisi, Director
Kathryn Kornafel, Senior Development
Robert Willens, Independent Director
Jonathan Feldschuh, Chief Scientific Officer, Director
Martin Wolpoff, Independent Director
Edward Feuer, Director
Eric Coleman, CFO
Linda Cooper, Vice Operations

Daxor Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Daxor a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Daxor in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Daxor's short interest history, or implied volatility extrapolated from Daxor options trading.

Pair Trading with Daxor

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Daxor position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Daxor will appreciate offsetting losses from the drop in the long position's value.

Moving against Daxor Stock

  0.65ENSG Ensign Group Financial Report 24th of April 2024 PairCorr
  0.57ISRG Intuitive Surgical Earnings Call This WeekPairCorr
  0.45ICUI ICU Medical Financial Report 13th of May 2024 PairCorr
The ability to find closely correlated positions to Daxor could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Daxor when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Daxor - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Daxor to buy it.
The correlation of Daxor is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Daxor moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Daxor moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Daxor can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Daxor is a strong investment it is important to analyze Daxor's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Daxor's future performance. For an informed investment choice regarding Daxor Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Daxor. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
To learn how to invest in Daxor Stock, please use our How to Invest in Daxor guide.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Complementary Tools for Daxor Stock analysis

When running Daxor's price analysis, check to measure Daxor's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Daxor is operating at the current time. Most of Daxor's value examination focuses on studying past and present price action to predict the probability of Daxor's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Daxor's price. Additionally, you may evaluate how the addition of Daxor to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Is Daxor's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Daxor. If investors know Daxor will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Daxor listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.58)
Earnings Share
0.14
Revenue Per Share
0.034
Quarterly Revenue Growth
(0.14)
Return On Assets
(0.02)
The market value of Daxor is measured differently than its book value, which is the value of Daxor that is recorded on the company's balance sheet. Investors also form their own opinion of Daxor's value that differs from its market value or its book value, called intrinsic value, which is Daxor's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Daxor's market value can be influenced by many factors that don't directly affect Daxor's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Daxor's value and its price as these two are different measures arrived at by different means. Investors typically determine if Daxor is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Daxor's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.